Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity (2016 - 2026)

Monopar Therapeutics has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $140.7 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 133.4% year-over-year to $140.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $393.9 million (up 377.69% YoY) and the FY2025 annual result came in at $140.7 million, up 133.4% from the prior year.
• Liabilities and Shareholders Equity eased to $140.7 million in Q4 2025 per MNPR's latest filing, from $144.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $144.2 million in Q3 2025 and troughed at $6.1 million in Q3 2024.
• A 5-year average of $33.5 million and a median of $17.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity plunged 44.47% in 2023, then surged 2275.71% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $20.5 million in 2021, then tumbled by 35.55% to $13.2 million in 2022, then sank by 44.47% to $7.3 million in 2023, then surged by 720.83% to $60.3 million in 2024, then jumped by 133.4% to $140.7 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $140.7 million, $144.2 million, and $53.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.